Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Tag: LLS
Beat AML study paves way for precision treatment
Using genetic information to match patients to targeted therapies may improve survival in people with a fast-moving leukemia. Because acute myeloid leukemia is such a fast-moving and deadly cancer,...
Rapid precision medicine is feasible in fight against a formidable leukemia
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
An elaborate clinical trial aims a multitude of targeted therapies at one formidable cancer
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Fighting a formidable leukemia with an expansive clinical trial
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...